Search

for
Search:

Sort by

Research

30 / 1000+ results

research Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System

January 2026 in “Journal of Dermatological Treatment”

Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.

research Long-term treatment with finasteride: sexual adverse events and fracture rates

January 2002 in “European Urology Supplements”

Finasteride can cause sexual side effects like decreased libido and erectile dysfunction.

research Sexual adverse events-related to dutasteride e finasteride: analysis of real-life data from Eudra-Vigilance database

October 2021 in “European urology open science”

research Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system

August 2025 in “The Journal of Sexual Medicine”

Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.

Comments Concerning the Real Risk of Sexual Adverse Events Secondary to the Use of 5-Alpha-Reductase Inhibitors

research Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs

January 2016 in “Archivio italiano di urologia, andrologia”

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

research Case reports suggest a broader range of sexual adverse events in patients receiving finasteride [Propecia, Proscar] than previously reported,

April 2012 in “Reactions Weekly”

Finasteride may cause more sexual side effects than previously thought.

research Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System

7 citations , December 2017 in “Journal of the European Academy of Dermatology and Venereology”

Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.

research A Gender Hypothesis of sex disparities in adverse drug events

8 citations , November 2023 in “Social Science & Medicine”

Gendered social factors, not just biology, contribute to sex differences in adverse drug events.

Multidimensional Assessment of Adverse Events of Finasteride: A Real-World Pharmacovigilance Analysis Based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

research Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

March 2025 in “PLoS ONE”

Finasteride can cause long-term side effects like sexual dysfunction and depression.

research Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases

24 citations , October 2016 in “Oncotarget”

Finasteride has a higher risk of reproductive side effects than minoxidil.

research Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

August 2024 in “medRxiv (Cold Spring Harbor Laboratory)”

Finasteride has various adverse effects, including sexual dysfunction and mental health issues, which vary by age and gender.

research Finasteride: suicidality or psychological adverse events

November 2020 in “Reactions Weekly”

Finasteride use linked to increased suicidality in patients under 45.

research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study

69 citations , July 2015 in “Pharmacotherapy”

Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.

Association of 5-Alpha Reductase Inhibitors and Sexual Dysfunction: A RADAR Report

research Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report

February 2013 in “Journal of The American Academy of Dermatology”

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

research Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen: A Phase III Research Study of Female Sexual Dysfunction in Women on Testosterone Patch Without Estrogen (APHRODITE)

4 citations , February 2009 in “Obstetrical & Gynecological Survey”

Testosterone patches can modestly improve sexual function in postmenopausal women not on estrogen therapy.

research How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects

October 2021 in “International Journal of Andrology”

Finasteride, a hair loss drug, has unaddressed sexual side effects due to the manufacturer's inadequate safety measures and lack of additional studies.

research Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review

5 citations , January 2020 in “Skin appendage disorders”

Oral dutasteride works better for hair loss, but has more sexual side effects; intralesional dutasteride is a possible alternative.

Patient-Reported Outcomes of Topical Finasteride/Minoxidil Treatment for Male Androgenetic Alopecia: A Retrospective Study Using Telemedical Data

research Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data

May 2024 in “Journal of cosmetic dermatology”

Topical finasteride/minoxidil is effective but not better than oral finasteride for hair loss.

research Finasteride toxicity information: “limited”, “poor quality”, “biased”

April 2015 in “Reactions Weekly”

Finasteride toxicity information is limited, poor quality, and biased.

research Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms

8 citations , January 2011 in “Korean Journal of Andrology”

The doxazosin plus tamsulosin combination improved symptoms effectively with fewer side effects.

research A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome

35 citations , June 2018 in “Urology”

The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.

research Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.

April 2026 in “Zenodo (CERN European Organization for Nuclear Research)”

Post-exposure syndromes are persistent conditions caused by past exposures, needing unique interventions.

research Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.

April 2026 in “Zenodo (CERN European Organization for Nuclear Research)”

Post-Exposure Syndromes are persistent conditions caused by past exposures, needing unique interventions.

Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System

research Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System

July 2025 in “International Journal of Dermatology”

Topical finasteride may be safer than oral finasteride, but more research is needed.

research Adverse events with finasteride or dutasteride: FAERS

July 2018 in “Reactions Weekly”

Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.

research Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System

11 citations , July 2020 in “Scientific Reports”

Statins may be linked to reproductive organ conditions, and their risks should be monitored.

research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression

75 citations , January 2014 in “Korean Journal of Urology”

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Search

for
Search:

Research

research Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System

research Long-term treatment with finasteride: sexual adverse events and fracture rates

research Sexual adverse events-related to dutasteride e finasteride: analysis of real-life data from Eudra-Vigilance database

research Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system

research Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs

research Case reports suggest a broader range of sexual adverse events in patients receiving finasteride [Propecia, Proscar] than previously reported,

research Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System

research A Gender Hypothesis of sex disparities in adverse drug events

research Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

research Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases

research Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024

research Finasteride: suicidality or psychological adverse events

research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study

research Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report

research Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen: A Phase III Research Study of Female Sexual Dysfunction in Women on Testosterone Patch Without Estrogen (APHRODITE)

research How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects

research Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review

research Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data

research Finasteride toxicity information: “limited”, “poor quality”, “biased”

research Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms

research A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome

research Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.

research Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.

research Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System

research Adverse events with finasteride or dutasteride: FAERS

research Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System

research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression

research Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health

research Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health

research Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health